Synaptic alterations associated with depression and schizophrenia: potential as a therapeutic target.


INTRODUCTION:In recent years, the concept of 'synaptopathy' has been extended from neurodegenerative and neurological disorders to psychiatric diseases. According to this nascent line of research, disruption in synaptic structure and function acts as the main determinant of mental illness. Therefore, molecular systems and processes crucial for synaptic activity may represent promising therapeutic targets. AREAS COVERED:We review data on synaptic structural alterations in depression and schizophrenia and on specific molecular systems and/or mechanisms important for the maintenance of proper synaptic function. Specifically, we examine the involvement of the neuroligin system, the local protein translation, and the neurotrophin BDNF by reviewing clinical and preclinical studies, with particular attention to results provided by using animal models based on the role of stress in psychiatric diseases. Finally, we also discuss the impact of pharmacological treatment on these molecular systems/mechanisms. EXPERT OPINION:The relevance of synaptic dysfunctions in psychiatric diseases is undoubted and the potential to normalize, ameliorate, and shape such alterations by acting on molecular systems crucial to ensure synaptic function property is fascinating. However, future studies are required to elucidate several open issues.


Calabrese F,Riva MA,Molteni R




Has Abstract


2016-10-01 00:00:00












  • Calreticulin, a therapeutic target?

    abstract:INTRODUCTION:Calreticulin is an endoplasmic reticulum (ER) resident protein critical for maintaining Ca(2+) homeostasis and glycoprotein folding in the ER. The protein has also been identified on the cell surface of apoptotic and necrotic cells and implicated to play a role in immunogenic cell death and other extracell...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Eggleton P,Bremer E,Dudek E,Michalak M

    更新日期:2016-09-01 00:00:00

  • Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs.

    abstract::Changes in the levels of either the cannabinoid CB(1) receptors or of their endogenous ligands, anandamide and 2-arachidonoylglycerol, appear to be casual or consequential in many neurological disorders. Several examples of how such diseases may be treated by substances capable of selectively manipulating endocannabin...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章


    authors: Marzo VD,Bisogno T,De Petrocellis L

    更新日期:2001-06-01 00:00:00

  • Targeting sigma-1 receptor signaling by endogenous ligands for cardioprotection.

    abstract:INTRODUCTION:The sigma receptors, initially described as a subtype of opioid receptors, are now considered to be a unique receptor expressed in neonatal rat cardiomyocytes and in the plasma membrane of adult rat cardiomyocytes. A number of sigma receptor ligands influence cardiovascular function and the heart has bindi...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Bhuiyan MS,Fukunaga K

    更新日期:2011-02-01 00:00:00

  • The proteasome as a target for protozoan parasites.

    abstract::Introduction: The proteasome is a multi-subunit enzyme complex responsible for the turnover of short-lived, abnormal or damaged proteins in eukaryotic cells. As organisms that undergo rapid growth and cell division, protozoan parasites exist on the knife-edge of proteotoxic catastrophe and thus rely heavily on their p...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Xie SC,Dick LR,Gould A,Brand S,Tilley L

    更新日期:2019-11-01 00:00:00

  • The continuing complexities of high-density lipoprotein metabolism in drug discovery and development.

    abstract::The termination of the Phase III clinical trial of Pfizer's CETP inhibitor torcetrapib, Investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE), due to excess mortality in the treatment group raised many questions for those involved in the discovery and development of dr...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 社论


    authors: Suckling K

    更新日期:2007-09-01 00:00:00

  • Preclinical insights into cholangiopathies: disease modeling and emerging therapeutic targets.

    abstract:INTRODUCTION:The common predominant clinical features of cholangiopathies such as primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), and biliary atresia (BA) are biliary damage/senescence and liver fibrosis. Curative therapies are lacking, and liver transplantation is the only option. An understan...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Sato K,Glaser S,Kennedy L,Liangpunsakul S,Meng F,Francis H,Alpini G

    更新日期:2019-06-01 00:00:00

  • Status of research on matrix metalloproteinases (MMPs) in India.

    abstract:INTRODUCTION:MMPs are extracellular matrix (ECM)-degrading enzymes that play a crucial role in embryogenesis, tissue remodeling, inflammation and angiogenesis. MMP-2 and -9 (also called type 2 and type 4 collagenase, or gelatinase A and B) are the key molecules that control invasion, tumor growth and metastasis. Tissue...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 社论


    authors: Bulbule A,Saraswati S,Kundu GC

    更新日期:2011-06-01 00:00:00

  • Targeting the EGFR T790M mutation in non-small-cell lung cancer.

    abstract:INTRODUCTION:The presence of activating mutations of the epidermal growth factor receptor (EGFR) is predictive of response to first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with advanced non-small-cell lung cancer (NSCLC). However, patients that initially respond to these drugs inexorably be...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Normanno N,Maiello MR,Chicchinelli N,Iannaccone A,Esposito C,De Cecio R,D'alessio A,De Luca A

    更新日期:2017-02-01 00:00:00

  • Targeting syndecans: a promising strategy for the treatment of cancer.

    abstract:INTRODUCTION:Syndecans are cell surface adhesion receptors that play important functional roles. Their deregulation has been linked to several pathologies, and their aberrant regulation via diverse mechanisms is critically involved in the pathogenesis of various cancers. Similar to other receptors, syndecan functions a...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Choi S,Kang DH,Oh ES

    更新日期:2013-06-01 00:00:00

  • Targeting frameshifting in the human immunodeficiency virus.

    abstract:INTRODUCTION:HIV-1 uses a programmed –1 ribosomal frameshift to generate Gag-Pol, the precursor of its enzymes, when its full-length mRNA is translated by the ribosomes of the infected cells. This change in the reading frame occurs at a so-called slippery sequence that is followed by a specific secondary structure, the...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Brakier-Gingras L,Charbonneau J,Butcher SE

    更新日期:2012-03-01 00:00:00

  • Cell adhesion and cancer: is there a potential for therapeutic intervention?

    abstract::Carcinogenesis involves a disruption in adhesion molecule expression and tissue architecture, and tumour invasion requires adhesion-dependent migration into surrounding tissues. Therefore, a variety of peptide and antibody-based reagents that block integrins, cadherins, immunoglobulin superfamily and selectin adhesion...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 社论


    authors: Lafrenie RM,Buckner CA,Bewick MA

    更新日期:2007-06-01 00:00:00

  • The high mobility group A1 molecular switch: turning on cancer - can we turn it off?

    abstract:INTRODUCTION:Emerging evidence demonstrates that the high mobility group A1 (HMGA1) chromatin remodeling protein is a key molecular switch required by cancer cells for tumor progression and a poorly differentiated, stem-like state. Because the HMGA1 gene and proteins are expressed at high levels in all aggressive tumor...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Huso TH,Resar LM

    更新日期:2014-05-01 00:00:00

  • Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression.

    abstract:BACKGROUND:TGF-beta regulates prostate growth by inhibiting epithelial cell proliferation and inducing apoptosis through eliciting a dynamic signaling pathway. In metastatic prostate cancer, however, TGF-beta serves as a tumor promoter. TGF-beta engages Smad-dependent and Smad-independent mechanisms to exert its action...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Jones E,Pu H,Kyprianou N

    更新日期:2009-02-01 00:00:00

  • The therapeutic uses of chromatin-modifying agents.

    abstract::In contrast to genetic aberrations, epigenetic aberrations can be reversed by the use of histone acetyltransferase (HAT), histone deacetylase (HDAC), SIRT, or histone methyltransferase (HMT) inhibitors. A well-known HDACi, suberoylanilide hydroxamic acid, has been recently approved for the treatment of cutaneous T cel...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Mai A

    更新日期:2007-06-01 00:00:00

  • The apelinergic system: a promising therapeutic target.

    abstract:IMPORTANCE OF THE FIELD:Apelin is a bioactive peptide known as the ligand of the G-protein-coupled receptor APJ. In recent years, there has been a growing body of evidence regarding the importance of apelin and APJ in the pathophysiology of cardiovascular, metabolic and gastrointestinal diseases, brain signalling, HIV ...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Falcão-Pires I,Ladeiras-Lopes R,Leite-Moreira AF

    更新日期:2010-06-01 00:00:00

  • Transcriptional regulation of Mcl-1 plays an important role of cellular protective effector of vincristine-triggered autophagy in oral cancer cells.

    abstract:OBJECTIVE:The autophagy-associated release of HMGB1 (high-mobility group box 1) has been reported that protect cancer cells from numerous chemotherapeutics. However, the related molecular mechanism involved in the protection of oral cancer cells remains unclear. RESEARCH DESIGN AND METHODS:In this study, we determined...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章


    authors: Hsieh MJ,Hsieh YH,Lin CW,Chen MK,Yang SF,Chiou HL

    更新日期:2015-04-01 00:00:00

  • Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer.

    abstract:INTRODUCTION:Systemic chemotherapy is a curative approach to inhibit gastric cancer cells proliferation. Despite the great progress in anti-cancer treatment achieved during the last decades, drug resistance and treatment refractoriness still extensively persists. Recently, accumulating studies have highlighted the role...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Yang W,Ma J,Zhou W,Cao B,Zhou X,Yang Z,Zhang H,Zhao Q,Fan D,Hong L

    更新日期:2017-11-01 00:00:00

  • The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer.

    abstract::Great inroads have been made in defining the oncogenic pathways intrinsic to neoplastic cells and the mechanisms by which they are activated in tumors. Knowledge of these pathways provides numerous opportunities that are actively being pursued to develop targeted therapies for cancer. Complementary studies, focused on...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Puré E

    更新日期:2009-08-01 00:00:00

  • Mantle cell lymphoma: insights into therapeutic targets at the preclinical level.

    abstract:INTRODUCTION:Mantle cell lymphoma (MCL) is a chronically relapsing B-cell non-Hodgkin lymphoma characterized by recurrent molecular-cytogenetic aberrations that lead to deregulation of DNA damage response, cell cycle progression, epigenetics, apoptosis, proliferation, and motility. In the last 10 years, clinical approv...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章


    authors: Klener P

    更新日期:2020-10-01 00:00:00

  • Exploiting the therapeutic potential of microRNAs in human cancer.

    abstract::Dysregulation of microRNAs (miRNAs) has been widely shown to be associated with the development and progression of cancer. Recent studies discovered a handful of miRNAs with great potential to act as therapeutic targets in various human cancers. Inhibition or overexpression of these oncomirs may regulate the expressio...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 社论


    authors: Cho WC

    更新日期:2012-04-01 00:00:00

  • Targeting testis-specific proteins to inhibit spermatogenesis: lesson from endocrine disrupting chemicals.

    abstract:INTRODUCTION:Exposure to endocrine disrupting chemicals (EDCs) has recently been linked to declining fertility in men in both developed and developing countries. Since many EDCs possess intrinsic estrogenic or androgenic activities, thus, the gonad is one of the major targets of EDCs. AREAS COVERED:For the past 2 deca...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Wan HT,Mruk DD,Wong CK,Cheng CY

    更新日期:2013-07-01 00:00:00

  • Contributions of P2X3 homomeric and heteromeric channels to acute and chronic pain.

    abstract::ATP acts as a fast neurotransmitter by activating a family of ligand-gated ion channels, the P2X receptors. Functional homomeric (P2X(3)) and heteromeric (P2X(2/3)) receptors are highly localised on primary sensory afferent neurons that transmit nociceptive sensory information. Activation of these P2X(3)containing cha...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Jarvis MF

    更新日期:2003-08-01 00:00:00

  • Inhibition of aggregate formation as therapeutic target in protein misfolding diseases: effect of tetracycline and trehalose.

    abstract:IMPORTANCE OF THE FIELD:The identification of molecules that inhibit protein deposition or reverse fibril formation could open new strategies for therapeutic intervention in misfolding diseases. Numerous compounds have been shown to inhibit amyloid fibril formation in vitro. Among these compounds, tetracycline and the ...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Sirangelo I,Irace G

    更新日期:2010-12-01 00:00:00

  • Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.

    abstract:INTRODUCTION:The MAPK pathway comprises several key signaling components and phosphorylation events that play a role in tumorigenesis. These activated kinases transmit extracellular signals that regulate cell growth, differentiation, proliferation, apoptosis and migration functions. Alteration of the RAS-RAF-MEK-ERK-MA...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Santarpia L,Lippman SM,El-Naggar AK

    更新日期:2012-01-01 00:00:00

  • Targeting ASK1 in ER stress-related neurodegenerative diseases.

    abstract::The accumulation of malfolded proteins in the endoplasmic reticulum (ER) induces ER stress, leading to the disturbance of ER function. To restore ER function and ER homeostasis, cells possess a highly specific ER quality control system termed the unfolded protein response (UPR), which increases the capacity of protein...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Homma K,Katagiri K,Nishitoh H,Ichijo H

    更新日期:2009-06-01 00:00:00

  • Sphingosine-1-phosphate: an emerging therapeutic target.

    abstract::Sphingosine-1-phosphate (SPP) is a polar sphingolipid metabolite that has received increasing attention as both an extracellular mediator and an intracellular second messenger. SPP is the ligand of a family of specific cell surface G-protein coupled receptors (GPCR), known as the endothelial differentiation gene-1 (ED...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章


    authors: Toman RE,Milstien S,Spiegel S

    更新日期:2001-02-01 00:00:00

  • Chromatin-modifying enzymes as therapeutic targets--Part 2.

    abstract:BACKGROUND:Part 1 of this review described the importance of histone acetylases, deacetylases, methylases and demethylases in transcriptional control and their potential as therapeutic targets. However, precise gene regulation requires the involvement of more than just the addition or removal of acetyl and methyl group...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Keppler BR,Archer TK

    更新日期:2008-11-01 00:00:00

  • Small-molecule modulators of Hh and Wnt signaling pathways.

    abstract::Hedgehog (Hh) and Wnt signaling pathways play key roles in growth and patterning during embryonic development and in the postembryonic regulation of stem cell number in the epithelia. Numerous studies link aberrant modulation of these pathways to specific human diseases. This article focuses on general aspects of Hh a...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Kiselyov AS,Tkachenko SE,Balakin KV,Ivachtchenko AV

    更新日期:2007-08-01 00:00:00

  • Decreased zinc in the development and progression of malignancy: an important common relationship and potential for prevention and treatment of carcinomas.

    abstract:INTRODUCTION:Efficacious chemotherapy does not exist for treatment or prevention of prostate, liver, and pancreatic carcinomas, and some other cancers that exhibit decreased zinc in malignancy. Zinc treatment offers a potential solution; but its support has been deterred by adverse bias. Areas covered: 1. The clinical ...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Costello LC,Franklin RB

    更新日期:2017-01-01 00:00:00

  • Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.

    abstract::Introduction. Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory cytokine with upstream regulatory roles in innate and adaptive immunity and is implicated in the pathogenesis of autoimmune diseases including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Several classes of MI...

    journal_title:Expert opinion on therapeutic targets

    pub_type: 杂志文章,评审


    authors: Bilsborrow JB,Doherty E,Tilstam PV,Bucala R

    更新日期:2019-09-01 00:00:00